Needham & Company LLC reaffirmed their buy rating on shares of Celcuity (NASDAQ:CELC - Free Report) in a research report released on Friday morning,Benzinga reports. Needham & Company LLC currently has a $29.00 price objective on the stock.
Separately, HC Wainwright reissued a "buy" rating and issued a $27.00 price target on shares of Celcuity in a research report on Tuesday, April 1st. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Celcuity currently has an average rating of "Buy" and an average target price of $30.17.
Get Our Latest Report on Celcuity
Celcuity Trading Down 1.9 %
Shares of NASDAQ:CELC traded down $0.19 during midday trading on Friday, reaching $9.92. The company had a trading volume of 135,757 shares, compared to its average volume of 286,643. The company has a fifty day simple moving average of $10.44 and a two-hundred day simple moving average of $12.42. The firm has a market cap of $375.36 million, a price-to-earnings ratio of -3.80 and a beta of 0.44. Celcuity has a 1-year low of $7.57 and a 1-year high of $19.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35.
Celcuity (NASDAQ:CELC - Get Free Report) last announced its earnings results on Monday, March 31st. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.13). Research analysts predict that Celcuity will post -2.62 earnings per share for the current year.
Institutional Investors Weigh In On Celcuity
A number of hedge funds have recently made changes to their positions in CELC. GAMMA Investing LLC raised its stake in shares of Celcuity by 1,237.4% in the first quarter. GAMMA Investing LLC now owns 1,324 shares of the company's stock valued at $131,000 after acquiring an additional 1,225 shares during the last quarter. Summit Investment Advisors Inc. boosted its stake in Celcuity by 49.5% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company's stock worth $45,000 after purchasing an additional 1,132 shares in the last quarter. Aquatic Capital Management LLC acquired a new position in Celcuity in the fourth quarter worth $50,000. Focus Financial Network Inc. bought a new stake in shares of Celcuity during the first quarter worth $108,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Celcuity in the fourth quarter valued at $142,000. Institutional investors and hedge funds own 63.33% of the company's stock.
About Celcuity
(
Get Free Report)
Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
Read More
Before you consider Celcuity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.
While Celcuity currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
